Literature DB >> 20616055

Kinase requirements in human cells: V. Synthetic lethal interactions between p53 and the protein kinases SGK2 and PAK3.

Amy Baldwin1, Dorre A Grueneberg, Karin Hellner, Jacqueline Sawyer, Miranda Grace, Wenliang Li, Ed Harlow, Karl Munger.   

Abstract

Cervical carcinomas are initiated through a series of well-defined stages that rely on the expression of human papillomavirus (HPV) oncogenes. A panel of 100 small hairpin RNAs that target essential kinases in many tumor types was used to study the stepwise appearance of kinase requirements during cervical tumor development. Twenty-six kinases were commonly required in three cell lines derived from frank carcinomas, and each kinase requirement was traced to the specific stage in which the requirement emerged. Six kinases became required following HPV-induced immortalization, and the requirement for two kinases, SGK2 and PAK3, was mapped to the inactivation of p53 in primary human epithelial cells. Loss of the p53 tumor suppressor in other primary epithelial cells also induced dependence on SGK2 and PAK3. Hence, SGK2 and PAK3 provide important cellular functions following p53 inactivation, fulfilling the classical definition of synthetic lethality; loss of p53, SGK2, or PAK3 alone has little effect on cell viability, whereas loss of p53 together with either SGK2 or PAK3 loss leads to cell death. Whereas tumor suppressor gene mutations are not directly druggable, other proteins or pathways that become obligatory to cell viability following tumor suppressor loss provide theoretical targets for tumor suppressor-specific drug discovery efforts. The kinases SGK2 and PAK3 may thus represent such targets for p53-specific drug development.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20616055      PMCID: PMC2906576          DOI: 10.1073/pnas.1007462107

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  42 in total

1.  Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells.

Authors:  Sonam Dolma; Stephen L Lessnick; William C Hahn; Brent R Stockwell
Journal:  Cancer Cell       Date:  2003-03       Impact factor: 31.743

2.  Lethal combinations.

Authors:  Chandra L Tucker; Stanley Fields
Journal:  Nat Genet       Date:  2003-11       Impact factor: 38.330

3.  Mutations in two matrix metalloproteinase genes, MMP-2 and MT1-MMP, are synthetic lethal in mice.

Authors:  Junseo Oh; Rei Takahashi; Eijiro Adachi; Shunya Kondo; Shinobu Kuratomi; Akinori Noma; David B Alexander; Hirotoshi Motoda; Akiko Okada; Motoharu Seiki; Takeshi Itoh; Shigeyoshi Itohara; Chiaki Takahashi; Makoto Noda
Journal:  Oncogene       Date:  2004-06-24       Impact factor: 9.867

4.  Kinase requirements in human cells: II. Genetic interaction screens identify kinase requirements following HPV16 E7 expression in cancer cells.

Authors:  Amy Baldwin; Wenliang Li; Miranda Grace; Joseph Pearlberg; Ed Harlow; Karl Münger; Dorre A Grueneberg
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-23       Impact factor: 11.205

5.  The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes.

Authors:  K Münger; W C Phelps; V Bubb; P M Howley; R Schlegel
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

6.  A TRAIL receptor-dependent synthetic lethal relationship between MYC activation and GSK3beta/FBW7 loss of function.

Authors:  Sabine Rottmann; Yan Wang; Marc Nasoff; Quinn L Deveraux; Kim C Quon
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-06       Impact factor: 11.205

7.  Multiple functions of human papillomavirus type 16 E6 contribute to the immortalization of mammary epithelial cells.

Authors:  Y Liu; J J Chen; Q Gao; S Dalal; Y Hong; C P Mansur; V Band; E J Androphy
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

Review 8.  Towards full employment: using RNAi to find roles for the redundant.

Authors:  Andrew Fraser
Journal:  Oncogene       Date:  2004-11-01       Impact factor: 9.867

9.  Specific synthetic lethal killing of RAD54B-deficient human colorectal cancer cells by FEN1 silencing.

Authors:  Kirk J McManus; Irene J Barrett; Yasaman Nouhi; Philip Hieter
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-13       Impact factor: 11.205

10.  Kinase requirements in human cells: I. Comparing kinase requirements across various cell types.

Authors:  Dorre A Grueneberg; Sebastien Degot; Joseph Pearlberg; Wenliang Li; Joan E Davies; Amy Baldwin; Wilson Endege; John Doench; Jacqueline Sawyer; Yanhui Hu; Frederick Boyce; Jun Xian; Karl Munger; Ed Harlow
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-23       Impact factor: 11.205

View more
  26 in total

Review 1.  Synthetic lethal interactions for the development of cancer therapeutics: biological and methodological advancements.

Authors:  Shinji Mizuarai; Hidehito Kotani
Journal:  Hum Genet       Date:  2010-10-26       Impact factor: 4.132

Review 2.  Systems genetics in "-omics" era: current and future development.

Authors:  Hong Li
Journal:  Theory Biosci       Date:  2012-11-09       Impact factor: 1.919

3.  Identification of TP53RK-Binding Protein (TPRKB) Dependency in TP53-Deficient Cancers.

Authors:  Moloy T Goswami; Kelly R VanDenBerg; Sumin Han; Lei Lucy Wang; Bhavneet Singh; Travis Weiss; Myles Barlow; Steven Kamberov; Kari Wilder-Romans; Daniel R Rhodes; Felix Y Feng; Scott A Tomlins
Journal:  Mol Cancer Res       Date:  2019-05-20       Impact factor: 5.852

Review 4.  Protein kinase signaling networks in cancer.

Authors:  John Brognard; Tony Hunter
Journal:  Curr Opin Genet Dev       Date:  2010-11-29       Impact factor: 5.578

5.  Human papillomaviruses as therapeutic targets in human cancer.

Authors:  Karin Hellner; Karl Münger
Journal:  J Clin Oncol       Date:  2011-01-10       Impact factor: 44.544

Review 6.  Towards systematic functional characterization of cancer genomes.

Authors:  Jesse S Boehm; William C Hahn
Journal:  Nat Rev Genet       Date:  2011-06-17       Impact factor: 53.242

Review 7.  Cancer associated human papillomaviruses.

Authors:  Margaret E McLaughlin-Drubin; Jordan Meyers; Karl Munger
Journal:  Curr Opin Virol       Date:  2012-06-02       Impact factor: 7.090

8.  MicroRNA 9-3p targets β1 integrin to sensitize claudin-low breast cancer cells to MEK inhibition.

Authors:  Jon S Zawistowski; Kazuhiro Nakamura; Joel S Parker; Deborah A Granger; Brian T Golitz; Gary L Johnson
Journal:  Mol Cell Biol       Date:  2013-03-25       Impact factor: 4.272

9.  Tumor-specific activation of the C-JUN/MELK pathway regulates glioma stem cell growth in a p53-dependent manner.

Authors:  Chunyu Gu; Yeshavanth K Banasavadi-Siddegowda; Kaushal Joshi; Yuko Nakamura; Habibe Kurt; Snehalata Gupta; Ichiro Nakano
Journal:  Stem Cells       Date:  2013-05       Impact factor: 6.277

Review 10.  Molecular Aspects of Head and Neck Cancer Therapy.

Authors:  Sidharth V Puram; James W Rocco
Journal:  Hematol Oncol Clin North Am       Date:  2015-10-17       Impact factor: 3.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.